CLEVELAND, Aug. 25, 2011 /PRNewswire/ -- What is the state of medical innovation in this new era of health care reform? What novel drugs are being developed to treat heart disease? Is cardiovascular innovation still a good investment opportunity? What do the top CEOs in the industry see as the biggest opportunities? Will IBM's Watson supercomputer be able to diagnose disease as well as practicing physicians?
These questions – and many others – will be discussed at Cleveland Clinic's 9th Annual Medical Innovation Summit Oct. 3-5. Registration is now open.
This year's Summit will focus on the heart and breakthrough technologies that will help diagnose and treat cardiovascular ailments. Heart failure currently affects 6 million Americans and top executives, investors, entrepreneurs, clinicians and technologists will gather to share ideas on how to effectively treat this burgeoning problem, as well as a host of other cardiovascular conditions.
"Cardiovascular care remains the largest market in all of medicine," says Chris Coburn, Executive Director of Cleveland Clinic Innovations. "Its history of innovation includes some of the most important technologies ever developed – heart transplantation, the artificial heart, heart pumps, pacemakers, stents, angiography, and hundreds more. The Summit will pinpoint what is coming next in cardiovascular care and what is the future for new technology in the current health care environment."
The Medical Innovation Summit attracts more than 1,000 leaders each year from more nearly two dozen countries. The three-day gathering will feature focused discussions with healthcare leaders, presentations by top medical innovators, and demonstrations of new heart therapies.
The 2011 Medical Innovation Summit speakers will feature more than 50 top health care leaders, including the CEOs of some of the most important companies in the industry: Ian Read (Pfizer), Jeffery Immelt (Gener
|SOURCE Cleveland Clinic|
Copyright©2010 PR Newswire.
All rights reserved